For US Healthcare Professionals

I am a

clinical improvement
clinical improvement

of patients maintained clinical improvement at each 8-week dosing interval, assessed through Week 52

DISCOVER 2: Maintenance of cDAPSA MCII† at each dosing interval‡

TREMFYA® (guselkumab) DISCOVER 2 response rate consistency data at 8-week dosing intervals
Zoom out
Zoom in
dose graph
dose graph

Indicates when TREMFYA® doses were administered. In DISCOVER 2, TREMFYA® doses were administered via prefilled syringe.

These endpoints were not adjusted for multiplicity. Therefore, statistical significance has not been established.

This post-hoc analysis evaluated consistency of improvement at start and end of each 8-week dosing interval in bio-naïve patients (n=248).||

cDAPSA is the sum of 4 domain scores that reflect PsA disease activity: swollen joint count, tender joint count, patient assessment of pain severity, and patient global assessment of arthritis.

cDAPSA=clinical Disease Activity Index for PsA; MCII=minimal clinically important improvements.

†MCII is defined as the smallest change in measurement that signifies an important improvement at the individual patient level.

‡The same patients may not have responded at each time interval.

§After Week 52, efficacy assessments of DISCOVER 2 were scheduled for visits >8 weeks apart.

||Proportion of patients who achieved MCII at previous visit and maintained MCII at the subsequent TREMFYA® q8w dosing visit (eg, achieved at Week 4 and maintained at Week 12). Only patients with available data in the outcome of interest for each pair of visits were included in the analysis of that outcome.

IN ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

TREMFYA® has optimized 8-week dosing and the One-Press patient-controlled injector

TREMFYA® is administered as a 100-mg subcutaneous injection once every 8 weeks, after 2 starter doses at Weeks 0 and 4.2

clinical improvement

injections per year*

TREMFYA® (guselkumab) dosing schedule for injections
dose time

Download the full Instructions for Use (IFU)

Watch TREMFYA® injection demonstration

The TREMFYA® 8-week dosing schedule was researched in clinical trials2,3

PsA dosage forms

  • Prefilled syringe 100 mg/mL (NDC: 57894-640-01)
  • One-Press patient-controlled injector 100 mg/mL (NDC: 57894-640-11)

Pretreatment Evaluations: Prior to initiating treatment with TREMFYA®, evaluate patients for tuberculosis infection and complete all age-appropriate vaccinations according to current immunization guidelines.

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training. In active PsA, TREMFYA® may be administered alone or in combination with a conventional DMARD (eg, methotrexate).

Download the full Instructions for Use (IFU)

Watch TREMFYA® injection demonstration

DMARD=disease-modifying antirheumatic drug; NDC=national drug code; PsA=psoriatic arthritis.

*Frequency of maintenance injections for TREMFYA® after the first year.

References: 1. Mease PJ, Baraliakos X, Chandran V, et al. Effect of guselkumab administered every 8 weeks in patients with active psoriatic arthritis persists between consecutive doses and is durable: post-hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study. Poster presented at European Alliance of Associations for Rheumatology (EULAR) Congress; Milan; June 2-5, 2023.
2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Data on file. Janssen Biotech, Inc.

Register for Updates